The identification and utilization of biomarkers such as matrix metalloproteinases (MMPs), urokinase plasminogen activator and its receptor (uPA/uPAR), myosin 5 A (MYO5A), survivin, and vascular endothelial growth factor (VEGF) have the potential to significantly enhance the prediction of pituitary tumor invasiveness. The gene discussed is PLAU; the disease is pituitary tumor.